Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus
Rev. Inst. Med. Trop. São Paulo (Online)
; 59: 67, Nov. 2017. ilus, tab
Artigo
em Inglês
| Sec. Est. Saúde SP, SESSP-IIERPROD, Sec. Est. Saúde SP
| ID: biblio-1023647
Biblioteca responsável:
BR31.1
Localização: BR31.1; 2017_P-034
ABSTRACT
Despite recent advances in therapy for chronic hepatitis C (CHC), the disease caused by genotype 3 virus (GEN3) is still considered a treatment challenge in certain patient subgroups. The aim of this retrospective study was to evaluate the effectiveness and safety of the peginterferon (Peg-IFN) and ribavirin (RBV) combination treatment for GEN3/CHC patients, and to evaluate sustained virological response (SVR) indicators and early treatment interruption due to serious adverse events (SAE). This was a retrospective observational study of GEN3/CHC patients, co-infected or not by HIV and treated with Peg-IFN/RBV in nine Brazilian healthcare centers. The study sample included 184 GEN3/CHC patients; 70 (38%) were co-infected with HIV. The overall SVR rate was 57.1% (95% CI 50-64). Among co-infected and mono-infected patients, the SVR rate was 51.4% (36/70) and 60.5% (69/114), respectively (p=0.241). Thirty-four (18.5%) patients experienced SAE and interrupted treatment. SVR was negatively associated with the use of Peg-IFN alpha 2b (PR 0.75; 95% CI 0.58-0.99; p=0.045) and to early treatment interruption due to SAE (PR 0.36; 95% CI 0.20-0.68; p=0.001). Early treatment interruption due to SAE was associated with age (PR 1.06; 95% CI 1.02-1.10; p<0.001) and occurrence of liver cirrhosis (PR 2.06; 95% CI 1.11-3.83; p=0.022). In conclusion, Peg-IFN/RBV might represent an adequate treatment option, mainly in young patients without advanced liver disease or when the use of direct-action drugs is limited to specific patient groups
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Brasil
Base de dados:
Sec. Est. Saúde SP
/
SESSP-IIERPROD
Assunto principal:
Interferons
/
Hepatite C
/
Hepacivirus
Tipo de estudo:
Estudo observacional
/
Fatores de risco
Limite:
Humanos
Idioma:
Inglês
Revista:
Rev. Inst. Med. Trop. São Paulo (Online)
Ano de publicação:
2017
Tipo de documento:
Artigo
Instituição/País de afiliação:
Secretaria Estadual de Saúde. Distrito Federal/BR
/
Secretaria de Estado da Saúde. São Paulo/BR
/
Universidade Federal de São Paulo/BR
/
Universidade Federal do Espírito Santo/BR
/
Universidade Federal do Estado do Rio de Janeiro/BR
/
Universidade de São Paulo/BR
/
Universidade do Sul de Santa Catarina/BR